HEARTFLOW, INC.

Lobbying for HEARTFLOW, INC. · Medical device firm in the cardiology space

Filing · LD-2 quarterly report Q3 report

Reporting period

3rd Quarter 2026

July 1 - Sep 30 · Posted Oct 20, 2026

Expenses

$100,000

What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.

Client based in

California

Official filing document

Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Medicare/Medicaid

Issues related to physician payments; issues related to Medicare reimbursement; issues related to Medicare reimbursement of AI-enabled technology; Ensuring Patient Access to Critical Breakthrough Products Act (S. 1717/H.R. 5343); Health Tech Investment Act (S. 1399/H.R. 6197); H.R. 9260, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027, issues related to health care, generally.

Bills named in this filing 5

S. 1717
Ensuring Patient Access to Critical Breakthrough Products Act of 2025
H.R. 5343
Ensuring Patient Access to Critical Breakthrough Products Act
S. 1399
Health Tech Investment Act
H.R. 6197
Health Tech Investment Act
H.R. 9260
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2027

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.